Yervoy (Intravenous)
Yervoy (Intravenous) Uses, Dosage, Side Effects, Food Interaction and all others data.
Yervoy (Intravenous) is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Yervoy (Intravenous) was developed by Bristol-Myers Squibb and Medarex.
Yervoy (Intravenous) was granted FDA approval on 25 March 2011.
Yervoy (Intravenous) is a human IgG1 that binds CTLA-4, preventing 1 T-cell inhibition signal pathway. It has a long duration of action as it is given every 3 to 4 weeks. Patients should be counselled regarding the risk of immune-mediated adverse effects, infusion related reactions, and embryo-fetal toxicity.
| Trade Name | Yervoy (Intravenous) |
| Availability | Prescription only |
| Generic | Ipilimumab |
| Ipilimumab Other Names | Ipilimumab |
| Related Drugs | Opdivo, Yervoy, Keytruda, capecitabine, pembrolizumab, Avastin, bevacizumab, Xeloda, nivolumab, atezolizumab |
| Type | |
| Formula | C6572H10126N1734O2080S40 |
| Weight | 148000.0 Da |
| Protein binding | Data regarding the protein binding of ipilimumab is not readily available. |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | USA |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Yervoy (Intravenous) is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma.
Yervoy (Intravenous) is indicated to treat unresectable or metastatic melanoma, as an adjuvant in the treatment of cutaneous melanoma, to treat microsatellite-high or mismatch repair deficient metastatic colorectal cancer, or to treat hepatocellular carcinoma. Yervoy (Intravenous) with nivolumab is indicated to treat advanced renal cell carcinoma.
Yervoy (Intravenous) is also used to associated treatment for these conditions: Advanced Renal Cell Carcinoma, Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Melanoma, Unresectable Melanoma, Metastatic MSI-H/dMMR colorectal cancer
How Yervoy (Intravenous) works
Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an inhibitory molecule that competes with the stimulatory CD28 for binding to B7 on antigen presenting cells. CTLA-4 and CD28 are both presented on the surface of T-cells. Yervoy (Intravenous) is a human IgG1 that binds CTLA-4, preventing the inhibition of T-cell mediated immune responses to tumors.
Toxicity
Data regarding ipilumumab overdose is not readily available. However, the most common adverse reactions to ipilumumab are fatigue, diarrhea, pruritus, rash, and colitis.
Food Interaction
No interactions found.Yervoy (Intravenous) Drug Interaction
Major: apixabanModerate: paclitaxel protein-bound, rosuvastatinUnknown: lactobacillus acidophilus, charcoal, amphetamine / dextroamphetamine, doxorubicin, ubiquinone, chondroitin / glucosamine / methylsulfonylmethane, sodium iodide, pembrolizumab, metoprolol, nivolumab, acetaminophen, docusate/senna, multivitamin, cyanocobalamin, cholecalciferol, menaquinone, cetirizine
Yervoy (Intravenous) Disease Interaction
Major: dermatitis, endocrinopathies, enterocolitis, hepatitis, neuropathies, ocular diseaseModerate: hepatic impairment
Volume of Distribution
The volume of distribution at steady-state of ipilimumab is 7.21L.
Elimination Route
Cmax was 65.8µg/mL for 2-6 year olds, 70.1µg/mL for 6-5 Data regarding the AUC and Tmax of ipilumumab are not readily available.
Half Life
Yervoy (Intravenous) has a half life of 14.7 days.
Clearance
Yervoy (Intravenous) has a clearance of 15.3 mL/hr. Systemic clearance increases proportionally with body weight.
Elimination Route
Data regarding the route of elimination of ipilimumab is not readily available.
Innovators Monograph
You find simplified version here Yervoy (Intravenous)
